Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
perospirone
- Development stage
- Phase 4
- Lead developer
- Sumitomo Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Perospirone is an atypical (second-generation) antipsychotic of the azapirone family. It acts primarily as an antagonist at serotonin 5-HT2A and dopamine D2 receptors, with additional activity as a partial agonist at 5-HT1A receptors. Perospirone also antagonizes dopamine D4, α1-adrenergic, and histamine H1 receptors. These combined actions are believed to improve both positive and negative symptoms of schizophrenia by modulating dopaminergic and serotonergic neurotransmission in various brain pathways. Developed by Dainippon Sumitomo Pharma (now Sumitomo Pharma), it was introduced in Japan for the treatment of schizophrenia and acute bipolar mania[3][4][6]. Perospirone is not approved in the US or EU but is marketed in Japan under the brand name Lullan[3][6].
- Brand names
- Lullan
- Other names
- perospironeSM-9018SM9018SM 9018Lullan
02
Targets
DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HRH1 (Histamine H1 Receptor)ADRA1 (Alpha-1 adrenergic receptor family)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on perospirone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on perospirone.